Table 5. Types of response and characteristics of the patients that either failed DAA-treatment (first two rows) or had detectable viral RNA at the end of DAA treatment (week 12) but finally were responders (week 24).

Type of response to INF α2a/RBV 2005–2013	DAA Treatment 2017	Gender	Age	Elastography (Kpa)	Cirrhosis, CPS	Viral subtype	Initial viral load (Log10 IU/mL)	HCV RNA at week 12 (end of treatment)	HCV RNA at week 24	Type of response to DAAs	SVR 12
Null response	OBV/PTV/r/DSV	M	59	7.3	No	1b	6.5	Not detected	1.62Log10 UI/mL	Relapse	No
Breakthrough	OBV/PTV/r/DSV+RBV	M	33	4.3	No	1a	5.7	5.29Log10 IU/mL	5.10Log10 UI/mL	Null response	No
Null response	OBV/PTV/r/DSV	F	50	31.4	Yes, CPS-A	1b	5.7	*Detected	Not detected	Responder	Yes
Relapse	OBV/PTV/r/DSV	F	54	5.3	No	1b	5.3	*Detected	Not detected	Responder	Yes
Relapse	OBV/PTV/r/DSV+RBV	F	56	5.5	No	*1a	5.3	*Detected	Detected/ Not detected at week 36a	Responder	Yes
Null response	OBV/PTV/r/DSV	M	50	5.5	No	1b	5.4	*Detected	Not detected	Responder	Yes
Relapse	OBV/PTV/r/DSV	F	52	11	No	1b	4.3	*Detected	Not detected	Responder	Yes
Null response	SOF/LDV	F	52	4.3	No	1a	6.0	*Detected	Not detected	Responder	Yes
Null response	SOF/LDV+RBV	F	52	19.8	Yes, CPS-A	1b	6.4	*Detected	Not detected	Responder	Yes
Null response	SOF/LDV+RBV	F	68	22.3	Yes, CPS-A	1a	5.5	*Detected	Not detected	Responder	Yes

Notes.

^*This patient had a HCV viral load below the LLOQ but above of LLOD at week 12 (end of treatment).

^aThis patient had a positive qualitative test at week 12 (end of treatment) and at week 24 (12 weeks post-treatment), that became undetectable at week 36 (24 weeks post-treatment).

M

Male

F

Female

Kpa

Kilopascals

CPS

Child Pugh Score

LLOQ

Lower limit of quantification (1.39 Log₁₀ IU/mL)

LLOD

Lower limit of detection (1.08Log₁₀ IU/mL)

SVR12

sustained virological response for DAA treatments.